LYON, France--(BUSINESS WIRE)-- Regulatory News:
POXEL (Paris:POXEL) (Euronext - FR0012432516), an independent French biopharmaceutical company focused on the development of antidiabetic drugs, today announces its schedule for the publication of financial information for 2015.
| Évent | Date * | ||
| 2014 Full-Year Sales | March 16, 2015 | ||
| 2014 Full-Year Financial statements | April 30, 2015 | ||
| 2015 Q1 Sales | May 5, 2015 | ||
| Annual Shareholders’ Meeting | June 16, 2015 | ||
| 2015 Q2 Sales | July 15, 2015 | ||
| 2015 June 30th, Financial statements | August 31, 2015 | ||
| 2015 Q3 Sales | October 22, 2015 | ||
| 2015 Full-Year Sales | January 28, 2016 |
* Subject to modification. Press releases are published after market closes.
About Poxel
Poxel uses its unique development expertise in metabolism to advance a pipeline of truly novel products currently focused on type 2 diabetes. Our first-in-class lead product, Imeglimin, targeting mitochondrial dysfunction, has successfully completed Phase 2 development in the US and EU and has entered clinical development in Japan. We are advancing our second program, PXL770, a direct AMPK activator, through clinical proof-of-concept. We will generate further growth through strategic partnerships and pipeline development. (Euronext: POXEL, www.poxel.com)
Investor / Media Relations - France
NewCap
Florent
Alba/Nicolas Merigeau
poxel@newcap.fr
+33
1 44 71 98 55
or
Investor / Media Relations – EU/US
MacDougall
Biomedical Communications
Gretchen Schweitzer or Anca Alexandru
aalexandru@macbiocom.com
+49
89 2424 3494
Source: POXEL
Released March 16, 2015